Genetics of rheumatoid arthritis contributes to biology and drug discovery (original) (raw)
References
- Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nature Rev. Drug Discov. 12, 581–594 (2013)
Article CAS Google Scholar - Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genet. 42, 508–514 (2010)
Article CAS Google Scholar - Okada, Y. et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nature Genet. 44, 511–516 (2012)
Article CAS Google Scholar - Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genet. 44, 1336–1340 (2012)
Article CAS Google Scholar - Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, e1003444 (2013)
Article CAS Google Scholar - Westra, H. J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nature Genet. 45, 1238–1243 (2013)
Article CAS Google Scholar - Raychaudhuri, S. et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet. 5, e1000534 (2009)
Article Google Scholar - Rossin, E. J. et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 7, e1001273 (2011)
Article CAS Google Scholar - Segrè, A. V., Groop, L., Mootha, V. K., Daly, M. J. & Altshuler, D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 6, e1001058 (2010)
Article Google Scholar - Stahl, E. A. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nature Genet. 44, 483–489 (2012)
Article CAS Google Scholar - 1000 Genomes Project Consortium et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012)
- Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nature Genet. 44, 291–296 (2012)
CAS Google Scholar - Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nature Genet. 45, 124–130 (2013)
Article CAS Google Scholar - Parvaneh, N., Casanova, J. L., Notarangelo, L. D. & Conley, M. E. Primary immunodeficiencies: a rapidly evolving story. J. Allergy Clin. Immunol. 131, 314–323 (2013)
Article Google Scholar - Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011)
Article CAS Google Scholar - Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A. & Richardson, J. E. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res. 40, D881–D886 (2012)
Article CAS Google Scholar - Knox, C. et al. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 39, D1035–D1041 (2011)
Article CAS Google Scholar - Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128–D1136 (2012)
Article CAS Google Scholar - Smolen, J. S. et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 72, 482–492 (2013)
Article CAS Google Scholar - Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19, 12–19 (2009)
Article CAS Google Scholar - McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011)
Article CAS Google Scholar - Sekine, C. et al. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J. Immunol. 180, 1954–1961 (2008)
Article CAS Google Scholar - Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nature Biotechnol. 30, 317–320 (2012)
Article CAS Google Scholar - Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988)
Article CAS Google Scholar - Okada, Y. et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nature Genet. 44, 904–909 (2012)
Article CAS Google Scholar - Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362–9367 (2009)
Article CAS ADS Google Scholar - Lage, K. et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nature Biotechnol. 25, 309–316 (2007)
Article CAS Google Scholar - Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511 (2003)
Article CAS ADS Google Scholar - Elliott, P. et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. J. Am. Med. Assoc. 302, 37–48 (2009)
Article CAS Google Scholar - Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genet. 45, 730–738 (2013)
Article CAS Google Scholar
Acknowledgements
R.M.P. is supported by National Institutes of Health (NIH) grants R01-AR057108, R01-AR056768, U01-GM092691 and R01-AR059648, and holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. Y.O. is supported by a grant from the Japan Society of the Promotion of Science. D.W. is supported by a grant from the Australian National Health and Medical Research Council (1036541). G.T. is supported by the Rubicon grant from the Netherlands Organization for Scientific Research. A.Z. is supported by a grant from the Dutch Reumafonds (11-1-101) and from the Rosalind Franklin Fellowship, University of Groningen. S.-C.B., S.-Y.B. and H.-S.L. are supported by the Korea Healthcare technology R&D project, Ministry for Health and Welfare (A121983). J.M., M.A.G.-G. and L.R.-R. are funded by the RETICS program, RIER, RD12/0009 from the Instituto de Salud Carlos III, Health Ministry. S.R.-D. and L.Ä.’s work is supported by the Medical Biobank of Northern Sweden. H.K.C. is supported by NIH (NIAMS) grants R01-AR056291, R01-AR065944, R01-AR056768, P60 AR047785 and R21 AR056042. L.P. and L.K. are supported by a senior investigator grant from the European Research Council. S.R. is supported by NIH grants R01AR063759-01A1 and K08-KAR055688A. P.M.V. is a National Health and Medical Research Council Senior Principal Research Fellow. M.A.B. is funded by the National Health and Medical Research Foundation Senior Principal Research Fellowship, and a Queensland State Government Premier’s Fellowship. H.X. is funded by the China Ministry of Science and Technology (973 program grant 2011CB946100), the National Natural Science Foundation of China (grants 30972339, 81020108029 and 81273283), and the Science and Technology Commission of Shanghai Municipality (grants 08XD1400400, 11410701600 and 10JC1418400). K.A.S. is supported by a Canada Research Chair, The Sherman Family Chair in Genomics Medicine, Canadian Institutes for Health Research grant 79321 and Ontario Research Fund grant 05-075. S.M. is supported by Health and Labour Sciences Research Grants. The BioBank Japan Project is supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government. This study is supported by the BE THE CURE (BTCure) project. We thank K. Akari, K. Tokunaga and N. Nishida for supporting the study.
Author information
Authors and Affiliations
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, 02115, Massachusetts, USA
Yukinori Okada, Di Wu, Gosia Trynka, Dorothée Diogo, Jing Cui, Katherine Liao, Michael H. Guo, Elizabeth W. Karlson, Soumya Raychaudhuri & Robert M. Plenge - Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, 02115, Massachusetts, USA
Yukinori Okada, Di Wu, Gosia Trynka, Towfique Raj, Dorothée Diogo, Jing Cui, Katherine Liao, Soumya Raychaudhuri, Philip L. De Jager & Robert M. Plenge - Program in Medical and Population Genetics, Broad Institute, Cambridge, 02142, Massachusetts, USA
Yukinori Okada, Di Wu, Gosia Trynka, Towfique Raj, Tõnu Esko, Namrata Gupta, Daniel Mirel, Dorothée Diogo, Jing Cui, Katherine Liao, Michael H. Guo, Soumya Raychaudhuri, Philip L. De Jager & Robert M. Plenge - Department of Statistics, Harvard University, Cambridge, 02138, Massachusetts, USA
Di Wu & Jun S. Liu - Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Clayton, Victoria 3800, Australia.,
Di Wu - Department of Neurology, Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Brigham and Women’s Hospital, Boston, 02115, Massachusetts, USA
Towfique Raj & Philip L. De Jager - Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.,
Chikashi Terao, Takahisa Kawaguchi & Fumihiko Matsuda - Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.,
Chikashi Terao, Koichiro Ohmura & Tsuneyo Mimori - Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo 162-0054, Japan.,
Katsunori Ikari, Shinji Yoshida, Atsuo Taniguchi, Hisashi Yamanaka & Shigeki Momohara - Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama 230-0045, Japan.,
Yuta Kochi, Akari Suzuki, Keiko Myouzen & Kazuhiko Yamamoto - Immunology Biomarkers Group, Genentech, South San Francisco, 94080, California, USA
Robert R. Graham, Arun Manoharan, Ward Ortmann, Tushar Bhangale & Timothy W. Behrens - Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, 37232, Tennessee, USA
Joshua C. Denny & Robert J. Carroll - Department of Medicine, Vanderbilt University School of Medicine, Nashville, 37232, Tennessee, USA
Joshua C. Denny & Anne E. Eyler - New York University Hospital for Joint Diseases, New York, 10003, New York, USA
Jeffrey D. Greenberg - Department of Medicine, Albany Medical Center and The Center for Rheumatology, Albany, 12206, New York, USA
Joel M. Kremer - Division of Rheumatology, Department of Medicine, New York, Presbyterian Hospital, College of Physicians and Surgeons, Columbia University, New York, 10032, New York, USA
Dimitrios A. Pappas - Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.,
Lei Jiang, Jian Yin, Lingying Ye & Huji Xu - Department of Pharmacology, Second Military Medical University, Shanghai 200433, China.,
Ding-Feng Su - University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, 4072, Queensland, Australia
Jian Yang, Peter M. Visscher & Matthew A. Brown - Queensland Brain Institute, The University of Queensland, Brisbane, 4072, Queensland, Australia
Jian Yang & Peter M. Visscher - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.,
Gang Xie & Katherine A. Siminovitch - Toronto General Research Institute, Toronto, Ontario M5G 2M9, Canada.,
Gang Xie & Katherine A. Siminovitch - Department of Medicine, University of Toronto, Toronto, Ontario M5S 2J7, Canada.,
Gang Xie & Katherine A. Siminovitch - Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto M5S 2J7, Canada.,
Ed Keystone - Department of Genetics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9700 RB, the Netherlands.,
Harm-Jan Westra, Alexandra Zhernakova & Lude Franke - Estonian Genome Center, University of Tartu, Riia 23b, Tartu 51010, Estonia.,
Tõnu Esko & Andres Metspalu - Division of Endocrinology, Children’s Hospital, Boston, 02115, Massachusetts, USA
Tõnu Esko & Michael H. Guo - School of Computer and Information Technology, Beijing Jiaotong University, Beijing 100044, China.,
Xuezhong Zhou - The Department of Psychiatry at Mount Sinai School of Medicine, New York, 10029, New York, USA
Eli A. Stahl - Department of Human Genetics, Radboud University Medical Centre, Nijmegen 6500 HB, the Netherlands.,
Marieke J. H. Coenen - Department of Rheumatology, Radboud University Medical Centre, Nijmegen 6500 HB, the Netherlands.,
Piet L. C. M. van Riel - Department of Rheumatology and Clinical Immunology, Arthritis Center Twente, University Twente & Medisch Spectrum Twente, Enschede 7500 AE, the Netherlands.,
Mart A. F. J. van de Laar - Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden 2300 RC, the Netherlands.,
Henk-Jan Guchelaar - Department of Rheumatology, Leiden University Medical Center, Leiden 2300 RC, the Netherlands.,
Tom W. J. Huizinga, Alexandra Zhernakova & Rene E. M. Toes - Service de Rhumatologie et INSERM U699 Hôpital Bichat Claude Bernard, Assistance Publique des Hôpitaux de Paris, Paris 75018, France.,
Philippe Dieudé - Université Paris 7-Diderot, Paris 75013, France.,
Philippe Dieudé - Institut National de la Santé et de la Recherche Médicale (INSERM) U1012, Université Paris-Sud, Rhumatologie, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre 94275, France.,
Xavier Mariette & Corinne Miceli-Richard - Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, 35294, Alabama, USA
S. Louis Bridges Jr - AMC/University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.,
Paul P. Tak - GlaxoSmithKline, Stevenage SG1 2NY, UK.,
Paul P. Tak - University of Cambridge, Cambridge CB2 1TN, UK.,
Paul P. Tak - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, South Korea.,
So-Young Bang, Hye-Soon Lee & Sang-Cheol Bae - Instituto de Parasitologia y Biomedicina Lopez-Neyra, CSIC, Granada 18100, Spain.,
Javier Martin - Department of Rheumatology, Hospital Marques de Valdecilla, IFIMAV, Santander 39008, Spain.,
Miguel A. Gonzalez-Gay - Hospital Clinico San Carlos, Madrid 28040, Spain.,
Luis Rodriguez-Rodriguez - Department of Public Health and Clinical Medicine, Umeå University, Umeå SE-901 87, Sweden.,
Solbritt Rantapää-Dahlqvist & Lisbeth Ärlestig - Department of Rheumatology, Umeå University, Umeå SE-901 87, Sweden.,
Solbritt Rantapää-Dahlqvist & Lisbeth Ärlestig - Department of Medicine, Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, 02115, Massachusetts, USA
Hyon K. Choi - Section of Rheumatology, Boston University School of Medicine, Boston, 02118, Massachusetts, USA
Hyon K. Choi - Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, 02118, Massachusetts, USA
Hyon K. Choi - Centre d’Etude du Polymorphisme Humain (CEPH), Paris 75010, France.,
Yoichiro Kamatani - Université Paris 13 Sorbonne Paris Cité, UREN (Nutritional Epidemiology Research Unit), Inserm (U557), Inra (U1125), Cnam, Bobigny 93017, France.,
Pilar Galan - McGill University and Génome Québec Innovation Centre, Montréal, Québec H3A 0G1 Canada.,
Mark Lathrop - Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9NT, UK.,
Steve Eyre, John Bowes, Anne Barton & Jane Worthington - National Institute for Health Research, Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9NT, UK.,
Steve Eyre, John Bowes & Jane Worthington - Department of Clinical Immunology and Rheumatology & Department of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.,
Niek de Vries - Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, 15261, Pennsylvania, USA
Larry W. Moreland - Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center for Arthritis, University of California San Francisco, San Francisco, 94117, California, USA
Lindsey A. Criswell - Unit of Statistical Genetics, Center for Genomic Medicine Graduate School of Medicine Kyoto University, Kyoto 606-8507, Japan.,
Ryo Yamada - Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama 230-0045, Japan.,
Michiaki Kubo - Department of Medicine (Solna), Rheumatology Unit, Karolinska Institutet, Stockholm SE-171 76, Sweden.,
Leonid Padyukov & Lars Klareskog - The Feinstein Institute for Medical Research, North Shore–Long Island Jewish Health System, Manhasset, 11030, New York, USA
Peter K. Gregersen - NIHR Manchester Musculoskeletal Biomedical, Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9NT, UK.,
Soumya Raychaudhuri - Section of Genetic Medicine, University of Chicago, Chicago, 60637, Illinois, USA
Barbara E. Stranger - Institute for Genomics and Systems Biology, University of Chicago, Chicago, 60637, Illinois, USA
Barbara E. Stranger - Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, Yokohama 230-0045, Japan.,
Atsushi Takahashi - Core Research for Evolutional Science and Technology (CREST) program, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan.,
Fumihiko Matsuda - Institut National de la Sante et de la Recherche Medicale (INSERM) Unite U852, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.,
Fumihiko Matsuda - Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo 113-0033, Japan.,
Kazuhiko Yamamoto
Authors
- Yukinori Okada
You can also search for this author inPubMed Google Scholar - Di Wu
You can also search for this author inPubMed Google Scholar - Gosia Trynka
You can also search for this author inPubMed Google Scholar - Towfique Raj
You can also search for this author inPubMed Google Scholar - Chikashi Terao
You can also search for this author inPubMed Google Scholar - Katsunori Ikari
You can also search for this author inPubMed Google Scholar - Yuta Kochi
You can also search for this author inPubMed Google Scholar - Koichiro Ohmura
You can also search for this author inPubMed Google Scholar - Akari Suzuki
You can also search for this author inPubMed Google Scholar - Shinji Yoshida
You can also search for this author inPubMed Google Scholar - Robert R. Graham
You can also search for this author inPubMed Google Scholar - Arun Manoharan
You can also search for this author inPubMed Google Scholar - Ward Ortmann
You can also search for this author inPubMed Google Scholar - Tushar Bhangale
You can also search for this author inPubMed Google Scholar - Joshua C. Denny
You can also search for this author inPubMed Google Scholar - Robert J. Carroll
You can also search for this author inPubMed Google Scholar - Anne E. Eyler
You can also search for this author inPubMed Google Scholar - Jeffrey D. Greenberg
You can also search for this author inPubMed Google Scholar - Joel M. Kremer
You can also search for this author inPubMed Google Scholar - Dimitrios A. Pappas
You can also search for this author inPubMed Google Scholar - Lei Jiang
You can also search for this author inPubMed Google Scholar - Jian Yin
You can also search for this author inPubMed Google Scholar - Lingying Ye
You can also search for this author inPubMed Google Scholar - Ding-Feng Su
You can also search for this author inPubMed Google Scholar - Jian Yang
You can also search for this author inPubMed Google Scholar - Gang Xie
You can also search for this author inPubMed Google Scholar - Ed Keystone
You can also search for this author inPubMed Google Scholar - Harm-Jan Westra
You can also search for this author inPubMed Google Scholar - Tõnu Esko
You can also search for this author inPubMed Google Scholar - Andres Metspalu
You can also search for this author inPubMed Google Scholar - Xuezhong Zhou
You can also search for this author inPubMed Google Scholar - Namrata Gupta
You can also search for this author inPubMed Google Scholar - Daniel Mirel
You can also search for this author inPubMed Google Scholar - Eli A. Stahl
You can also search for this author inPubMed Google Scholar - Dorothée Diogo
You can also search for this author inPubMed Google Scholar - Jing Cui
You can also search for this author inPubMed Google Scholar - Katherine Liao
You can also search for this author inPubMed Google Scholar - Michael H. Guo
You can also search for this author inPubMed Google Scholar - Keiko Myouzen
You can also search for this author inPubMed Google Scholar - Takahisa Kawaguchi
You can also search for this author inPubMed Google Scholar - Marieke J. H. Coenen
You can also search for this author inPubMed Google Scholar - Piet L. C. M. van Riel
You can also search for this author inPubMed Google Scholar - Mart A. F. J. van de Laar
You can also search for this author inPubMed Google Scholar - Henk-Jan Guchelaar
You can also search for this author inPubMed Google Scholar - Tom W. J. Huizinga
You can also search for this author inPubMed Google Scholar - Philippe Dieudé
You can also search for this author inPubMed Google Scholar - Xavier Mariette
You can also search for this author inPubMed Google Scholar - S. Louis Bridges Jr
You can also search for this author inPubMed Google Scholar - Alexandra Zhernakova
You can also search for this author inPubMed Google Scholar - Rene E. M. Toes
You can also search for this author inPubMed Google Scholar - Paul P. Tak
You can also search for this author inPubMed Google Scholar - Corinne Miceli-Richard
You can also search for this author inPubMed Google Scholar - So-Young Bang
You can also search for this author inPubMed Google Scholar - Hye-Soon Lee
You can also search for this author inPubMed Google Scholar - Javier Martin
You can also search for this author inPubMed Google Scholar - Miguel A. Gonzalez-Gay
You can also search for this author inPubMed Google Scholar - Luis Rodriguez-Rodriguez
You can also search for this author inPubMed Google Scholar - Solbritt Rantapää-Dahlqvist
You can also search for this author inPubMed Google Scholar - Lisbeth Ärlestig
You can also search for this author inPubMed Google Scholar - Hyon K. Choi
You can also search for this author inPubMed Google Scholar - Yoichiro Kamatani
You can also search for this author inPubMed Google Scholar - Pilar Galan
You can also search for this author inPubMed Google Scholar - Mark Lathrop
You can also search for this author inPubMed Google Scholar - Steve Eyre
You can also search for this author inPubMed Google Scholar - John Bowes
You can also search for this author inPubMed Google Scholar - Anne Barton
You can also search for this author inPubMed Google Scholar - Niek de Vries
You can also search for this author inPubMed Google Scholar - Larry W. Moreland
You can also search for this author inPubMed Google Scholar - Lindsey A. Criswell
You can also search for this author inPubMed Google Scholar - Elizabeth W. Karlson
You can also search for this author inPubMed Google Scholar - Atsuo Taniguchi
You can also search for this author inPubMed Google Scholar - Ryo Yamada
You can also search for this author inPubMed Google Scholar - Michiaki Kubo
You can also search for this author inPubMed Google Scholar - Jun S. Liu
You can also search for this author inPubMed Google Scholar - Sang-Cheol Bae
You can also search for this author inPubMed Google Scholar - Jane Worthington
You can also search for this author inPubMed Google Scholar - Leonid Padyukov
You can also search for this author inPubMed Google Scholar - Lars Klareskog
You can also search for this author inPubMed Google Scholar - Peter K. Gregersen
You can also search for this author inPubMed Google Scholar - Soumya Raychaudhuri
You can also search for this author inPubMed Google Scholar - Barbara E. Stranger
You can also search for this author inPubMed Google Scholar - Philip L. De Jager
You can also search for this author inPubMed Google Scholar - Lude Franke
You can also search for this author inPubMed Google Scholar - Peter M. Visscher
You can also search for this author inPubMed Google Scholar - Matthew A. Brown
You can also search for this author inPubMed Google Scholar - Hisashi Yamanaka
You can also search for this author inPubMed Google Scholar - Tsuneyo Mimori
You can also search for this author inPubMed Google Scholar - Atsushi Takahashi
You can also search for this author inPubMed Google Scholar - Huji Xu
You can also search for this author inPubMed Google Scholar - Timothy W. Behrens
You can also search for this author inPubMed Google Scholar - Katherine A. Siminovitch
You can also search for this author inPubMed Google Scholar - Shigeki Momohara
You can also search for this author inPubMed Google Scholar - Fumihiko Matsuda
You can also search for this author inPubMed Google Scholar - Kazuhiko Yamamoto
You can also search for this author inPubMed Google Scholar - Robert M. Plenge
You can also search for this author inPubMed Google Scholar
Consortia
the RACI consortium
the GARNET consortium
Contributions
Y.O. carried out the primary data analyses. D.W. managed drug target gene data. G.T. conducted histone mark analysis. T.R., H.-J.W., T.E., A.M., B.E.S., P.L.D. and L.F. conducted eQTL analysis. C.T., K.I., Y.K., K.O., A.S., S.Y., G.X., E.K. and K.A.S. conducted the de novo replication study. R.R.G., A.M., W.O., T.B., T.W.B., L.J., J. Yin, L.Y., D.-F.S., J. Yang, P.M.V., M.A.B. and H.X. conducted the in silico replication study. E.A.S., D.D., J.C., T.K., R.Y. and A.T. managed GWAS data. All other authors, as well as the members of the RACI and GARNET consortia, contributed to additional analyses and genotype and clinical data enrolments. Y.O. and R.M.P. designed the study and wrote the manuscript, with contributions from all authors on the final version of the manuscript.
Corresponding authors
Correspondence toYukinori Okada or Robert M. Plenge.
Ethics declarations
Competing interests
R.R.G., A.M., W.O., T.B. and T.W.B. are employees of Genentech. P.P.T. is an employee of GlaxoSmithKline. R.M.P. is currently employed by Merck & Company. The other authors declare no competing financial interests.
Additional information
Summary statistics from the GWAS meta-analysis, source codes, and data sources used in this study are available at http://plaza.umin.ac.jp/~yokada/datasource/software.htm.
Lists of participants and their affiliations appear in the Supplementary Information.
Lists of participants and their affiliations appear in the Supplementary Information.
Extended data figures and tables
Extended Data Figure 1 An overview of the study design.
a, We conducted a three-stage trans-ethnic meta-analysis in total of 29,880 RA cases and 73,758 controls of European (EUR) and Asian (ASN) ancestry. The stage 1 GWAS meta-analysis included 19,234 RA cases and 61,565 controls from 22 studies, which was followed by the stage 2 in silico replication study (3,708 RA cases and 5,535 controls) and stage 3 de novo replication study (6,938 RA cases and 6,658 controls). In the combined study of stages 1–3, we identified 42 novel RA risk loci, which increased the total number of RA risk loci to 101. b, Using the 100 RA risk loci (outside of the MHC region), we conducted trans-ethnic and functional annotation of the RA risk SNPs. We constructed an in silico bioinformatics pipeline to prioritize biological candidate genes. We adopted eight criteria to score each of 377 genes in the RA risk loci: (1) RA risk missense variant; (2) _cis_-eQTL; (3) PubMed text mining; (4) PPI; (5) PID; (6) haematological cancer somatic mutation; (7) knockout mouse phenotype; and (8) molecular pathway. Our study also demonstrated that these biological candidate genes in RA risk loci are significantly enriched in overlap with target genes for approved RA drugs.
Extended Data Figure 2 Quantile–quantile plots and Manhattan plots of P values in the GWAS meta-analysis.
a, Quantile–quantile plots of P values in the stage 1 GWAS meta-analysis for trans-ethnic, European and Asian ancestries. The _x_-axis indicates the expected −log10 (P values). The _y_-axis indicates the observed −log10 (P values) after the application of double GC correction. The SNPs for which observed P values were less than 1.0 × 10−20 are indicated at the upper limit of each plot. Black, blue and red dots represent the association results of all SNPs, SNPs outside of the MHC region and PTPN22 locus, and SNPs outside of the known RA risk loci, respectively. Double GC correction was applied based on the inflation factor, _λ_GC, which was estimated from the SNPs outside of the known RA loci and indicated in each plot. b, Manhattan plots of P values in the stage 1 GWAS meta-analysis for trans-ethnic, European and Asian ancestries. The _y_-axis indicates the −log10 (P values) of genome-wide SNPs in each GWAS meta-analysis. The horizontal grey line represents the genome-wide significance threshold of P = 5.0 × 10−8. The SNPs for which P values were less than 1.0 × 10−20 are indicated at the upper limit of each plot.
Extended Data Figure 3 Trans-ethnic and functional annotation of RA risk SNPs.
a, b, Comparisons of RAF and OR values between individuals of European (EUR) and Asian (ASN) ancestry from the stage 1 GWAS meta-analysis. ORs were defined based on minor alleles in Europeans. SNPs with _F_ST > 0.10 or SNPs in which the 95% CI of the OR did not overlap between Europeans and Asians are coloured. OR of the SNP in the HLA-DRB1 locus (≥1.5) is plotted at the upper limits of the _x_- and _y_-axes. Five loci demonstrated population-specific associations (P < 5.0 × 10−8 in one population but _P_ > 0.05 in the other population without overlap of the 95% CI of the OR) are highlighted by red labels (rs227163 at TNFRSF9, rs624988 at CD2, rs726288 at SFTPD, rs10790268 at CXCR5 and rs73194058 at IFNGR2). c, Cumulative curve of explained heritability in each population. d, Enrichment analysis for overlap of RA risk SNPs with H3K4me3 peaks in cell types. The most significant cell type is Treg primary cells. e, Number of SNPs in the process of trans-ethnic and functional fine mapping. For 31 loci in which the risk SNPs yielded P < 1.0 × 10−3 in both populations (stage 1 GWAS), the number of candidate causal variants was reduced by 40–70% when confined by SNPs in linkage disequilibrium with the RA risk SNPs (_r_2 > 0.80) in both populations (on average, from 21.9 or 37.3 SNPs in linkage disequiliberium in Europeans or Asians, to 15.0 SNPs in linkage disequilibrium in both populations). Further, for 10 loci in which candidate causal variants significantly overlapped with H3K4me3 peaks in Treg cells (P < 0.05), the average number of SNPs was further reduced by half again, from 10.4 to 5.9. f, Fine mapping in the CTLA4 locus, where the functional non-coding variant of CT60 (rs3087243)28 showed the most significant association with RA. The top three panels indicate regional SNP associations of the locus in the stage 1 GWAS meta-analysis for trans-ethnic, European and Asian ancestries, respectively. The bottom panel indicates the change in the number of the candidate causal variants in each process of fine mapping. Trans-ethnic fine mapping of candidate causal variants decreased the number of candidate variants from 44 (linkage disequilibrium in Asians) and 27 (linkage disequilibrium in Europeans) to 21 (linkage disequilibrium in both populations). As these SNPs were significantly enriched in overlap with H3K4me3 peaks in Treg cells compared with the surrounding SNPs (P = 0.037), we confined the candidate variants into nine by additionally selecting the SNPs included in H3K4me3 peaks. CT60 was included in these finally selected nine SNPs, and also located at the vicinity of a H3K4me3 peak summit (indicated by a red arrow).
Extended Data Figure 4 Pleiotropy of RA risk SNPs.
a, Definition of region-based and allele-based pleiotropy. For each of the RA risk SNPs and SNPs registered in the NHGRI GWAS catalogue (outside of the MHC region), we defined the region on the basis of ±25 kb of the SNP or the neighbouring SNP positions in moderate linkage disequilibrium with it in Europeans or Asians (_r_2 > 0.50). We defined ‘region-based pleiotropy’ as two phenotype-associated SNPs sharing part of their genetic regions or any UCSC hg19 reference gene(s) partly overlapping with each of the regions. We defined ‘allele-based pleiotropy’ as two phenotype-associated SNPs in linkage disequilibrium in Europeans or Asians (_r_2 > 0.80). b, Region-based pleiotropy of the RA risk loci. We found two-thirds of RA risk loci (n = 66) demonstrated region-based pleiotropy with other human phenotypes. Phenotypes which showed region-based pleiotropy with RA risk loci are indicated (P < 0.05). c, Allele-based pleiotropy of the RA risk loci. Allele-based pleiotropy with discordant directional effects to RA risk SNPs are indicated in grey. d, Relative proportions of pleiotropic effects (that is, regions and alleles that influence multiple phenotypes) between RA risk loci and 311 phenotypes from the NHGRI GWAS catalogue. Representative examples of disease and biomarker phenotypes are shown. One-quarter of the observed region-based pleiotropic associations (26% = 54/207) were also annotated as having allele-based pleiotropy, although their proportions and directional effects varied among phenotypes. e, Allele-based pleiotropy of IL6R 358Asp (rs2228145 (A))5 on multiple disease phenotypes, including increased risk of RA, ankylosing spondylitis and coronary heart disease (asterisks indicate associations obtained from the literature29,30) and protection from asthma, as well as levels of biomarkers (increased C-reactive protein (CRP) and fibrinogen but decreased soluble interleukin-6 receptor (sIL6R)).
Extended Data Figure 5 Overlap of RA risk SNPs with biological resources.
a, Missense variants in linkage disequilibrium (_r_2 > 0.80 in Europeans or Asians) with RA risk SNPs. When multiple missense variants are in linkage disequilibrium with the RA risk SNP, the highest _r_2 value is indicated. b, Functional annotation of the SNPs in 100 non-MHC RA risk loci, including the relative proportion of heritability explained by SNP annotations. Although 44% of all RA risk SNPs had _cis_-eQTL, 9 of them overlapped with missense or synonymous variants but 35 of them did not overlap as indicated by asterisks. A list of _cis_-eQTL SNPs and genes can be found in Extended Data Table 2. c, Overlap of RA risk genes with human PID and defined categories. d, Overlap of RA risk genes with cancer somatic mutation genes. In addition to the categories of all cancers, haematological cancers and non-haematological cancers, cancer types that showed overlap with ≥2 of RA risk genes are indicated. e, Overlap of RA risk genes with knockout mouse phenotypes. Knockout mouse phenotypes that satisfied significant enrichment with RA risk genes are indicated in bold (P < 0.05/30 = 0.0017). f, Molecular pathway analysis of RA GWAS results. Molecular pathways that showed significant enrichment in either the current stage 1 trans-ethnic GWAS meta-analysis or the previous GWAS meta-analysis of RA2 are indicated in bold (FDR q < 0.05).
Extended Data Figure 6 Prioritization of biological candidate genes from RA risk loci.
a, Prioritization criteria of biological candidate genes from RA risk loci. b, Histogram distribution of gene scores. The 98 genes with score ≥2 (orange) were defined as ‘biological RA risk genes’. c, Correlations of biological candidate gene prioritization criteria. d, Change in the overlapping proportions of genes with H3K4me3 peaks by cell type according to score increases. When RA risk SNP of the locus (or SNP in linkage disequilibrium) overlapped with H3K4me3 peaks, genes in the locus were defined as overlapping.
Extended Data Figure 7 Overlap of all genes in the RA risk loci with drug target genes.
a, Approved RA drugs and target genes. DMARDs, disease-modifying antirheumatic drugs. b, Overlap analysis stratified by immune-related and non-immune-related drug target genes. We made a list of 583 immune-related genes based on Gene Ontology (GO) pathways named ‘immune-’ or ‘immuno-’ and found that the majority of drug target genes (791/871 = 91%) were not immune-related. c, Overlap of all 377 genes included in 100 RA risk loci (outside of the MHC region) plus 3,776 genes in direct PPI with them and drug target genes. We found overlap of 19 genes from the 27 drug target genes of approved RA drugs (2.3-fold enrichment, P < 1.0 × 10−5). All 871 drug target genes (regardless of disease indication) overlap with 329 genes from the PPI network, which is 1.3-fold more enrichment than expected by chance alone (P < 1.0 × 10−5), but less than 1.7-fold enrichment compared with RA drugs (P = 0.0059). We note that this enrichment of drug–gene pairs was less apparent compared with that obtained from the expanded PPI network generated from 98 biological candidate genes (Fig. 3b).
Extended Data Figure 8 Connection between RA risk genes and approved RA drugs.
Full lists of the connections between RA risk SNPs (blue boxes), biological candidate genes from each risk locus (purple boxes), genes from the expanded PPI network (green boxes) and approved RA drugs (orange boxes). Black lines indicate connections. Only IL6R is a direct connection between an SNP–biological gene–drug (tocilizumab)19,20; all other SNP–drug connections are through the PPI network.
Extended Data Table 1 Characteristics of the study cohorts
Extended Data Table 2 _cis_-eQTL of RA risk SNPs
Supplementary information
Supplementary Information
This file contains Supplementary Tables 1-6 and a Supplementary Note. (PDF 449 kb)
Supplementary Data
This file contains the source data file for Supplementary Table 2. (XLSX 10 kb)
Supplementary Data
This file contains the source data file for Supplementary Table 3. (XLSX 24 kb)
Supplementary Data
This file contains the source data file for Supplementary Table 4. (XLSX 2583 kb)
Supplementary Data
This file contains the source data file for Supplementary Table 5. (XLSX 51 kb)
Supplementary Data
This file contains the source data file for Supplementary Table 6. (XLSX 17 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Okada, Y., Wu, D., Trynka, G. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery.Nature 506, 376–381 (2014). https://doi.org/10.1038/nature12873
- Received: 15 June 2013
- Accepted: 07 November 2013
- Published: 25 December 2013
- Issue Date: 20 February 2014
- DOI: https://doi.org/10.1038/nature12873